

# Association of Breast Surgery Conference

Monday 16th – Tuesday 17th May 2022  
ACC, Liverpool

# ABS

ASSOCIATION OF  
BREAST SURGERY

[www.associationofbreastsurgery.org.uk](http://www.associationofbreastsurgery.org.uk)



# Contents

- 1 Welcome
- 2 Programme Monday 16th May
- 5 Programme Tuesday 17th May
- 9 General Information
- 11 Trade exhibitors

## Welcome

### 2022 Association of Breast Surgery Conference



It gives me tremendous pleasure to welcome you to Liverpool for the 2022 Association of Breast Surgery Conference. After a gap of two years, we are looking forward to seeing you in person; to renewing old friendships and acquaintances and making new ones.

It has been a difficult two years during which the breast community have delivered a fantastic service under very trying circumstances, and we realise that even now those covid related difficulties are far from over. There remain unprecedented pressures on new patient referrals and a surgical backlog to tackle. If you are struggling do get in touch – a problem shared is a problem halved, and there is almost always someone who has experience of similar problems who can lend a listening ear.

Hopefully the meeting will provide some welcome respite from what can feel like a pressured day to day grind. We hope you will find good company and an academically stimulating meeting and conference programme. I will once again have the 'parallel session challenge', where I repeatedly want to attend two or even three of the parallel sessions being delivered at any one time. But please remember that the sessions are recorded and will be available for members to view after the conference.

I am delighted to welcome four excellent speakers for our invited lectures on:

- Fertility and pregnancy during and after breast cancer from Dr Ann Partridge
- Ethnicity and Breast Cancer in the UK from Miss Toral Gathani delivering her Hunterian Lecture
- Optimising surgical decision making for women at elevated breast cancer risk from Dr Stephanie Wong and
- The importance of bean counting in breast surgery – The future of coding, tariff and metrics from Mr Ken Dunn

Do please check out the posters via the screens in the hall and/or via the conference app.

We are very grateful to our sponsors who are once again generously supporting the conference. We could not do all that we do without them. Please do go and visit the stands. A special thank you also to our sponsors for their support during the last two years of the pandemic.

Liverpool is of course a great city to visit and has been rated as one of the top 10 destinations in the world to visit for a weekend, so why not come early, or stay on after the conference and take in the sights and sounds of the city.

Chris Holcombe  
ABS President



# Programme MONDAY 16TH MAY

08.00 TO 09.00	REGISTRATION, WELCOME REFRESHMENTS, EXHIBITION AND POSTER VIEWING				
	HALL 1A	ROOM 3	HALL 1C		LIVE LOUNGE
09.00 TO 10.20	<b>SESSION 1</b> AESTHETIC AND ONCOPLASTIC BREAST SURGERY SESSION	<b>SESSION 2</b> SYMPOSIUM MAMMOGRAPHICUM SESSION	<b>SESSION 3</b> NURSING SESSION		
10.20 TO 11.05	REFRESHMENTS, EXHIBITION AND POSTER VIEWING IN HALL 2			10.30 TO 11.30	ONCOPLASTIC BREAST SURGERY PAPERS SESSION
11.05 TO 11.35	<b>SESSION 4</b> INVITED LECTURE: FERTILITY AND PREGNANCY DURING AND AFTER BREAST CANCER				
11.40 TO 13.00	<b>SESSION 5</b> ABS AND RCOG GUIDELINES FOR MANAGEMENT OF PREGNANCY ASSOCIATED BREAST CANCER	<b>SESSION 6</b> ABS & UKBCG GUIDANCE ON NACT	<b>SESSION 7</b> INNOVATION SESSION		
13.00 TO 14.30	LUNCH, EXHIBITION AND POSTER VIEWING IN HALL 2				
13.15 TO 14.15		<b>SPONSORED SYMPOSIUM</b> EXACT SCIENCES		13.15 TO 13.35	ONCOPLASTIC BREAST SURGERY PAPERS Q&A SESSION WITH PRESENTERS
14.30 TO 15.50	<b>SESSION 8</b> ABS AUDITS SESSION	<b>SESSION 9</b> PERSONALISATION OF BREAST CANCER CARE: EVIDENCE FOR NOW AND THE FUTURE	<b>SESSION 10</b> MANAGING ENDOCRINE SIDE EFFECTS		
15.50 TO 16.30	REFRESHMENTS, EXHIBITION AND POSTER VIEWING IN HALL 2				
16.30 TO 17.00	<b>SESSION 11</b> HUNTERIAN LECTURE: ETHNICITY AND BREAST CANCER	<b>SESSION 12</b> MAMMARY FOLD POSTER PRIZE SESSION		16.00 TO 17.00	REFERRALS, DIAGNOSIS & SURVIVORSHIP PAPERS SESSION
17.15 TO 18.00		ABS AGM		17.00 TO 17.20	REFERRALS, DIAGNOSIS & SURVIVORSHIP PAPERS Q&A SESSION WITH PRESENTERS
17.00 TO 18.45	EXHIBITION AND POSTER VIEWING IN HALL 2				

## SESSION 1 09.00 to 10.20

HALL 1A

### AESTHETIC AND ONCOPLASTIC BREAST SURGERY SESSION

Chairs: Mr Lee Martin, Ms Ruth Waters and Ms Lucy Khan

- 09.00 Autologous augmentation**  
Miss Jo Skillman, University Hospital Coventry & Warwickshire
- 09.20 Are all breast reconstructions pre-pec now?**  
Miss Shelley Potter, North Bristol NHS Trust and Bristol Medical School
- 09.40 New ABS lipofilling guidelines**  
Miss Penny McManus, Royal Lancaster Infirmary
- 10.00 Q&A panel discussion with speakers**

## SESSION 2 09.00 to 10.20

ROOM 3

### SYMPOSIUM MAMMOGRAPHICUM SESSION

Chairs: Miss Leena Chagla and Miss Michelle Mullan

- 09.00 Intelligent use of breast MRI**  
Dr Nisha Sharma, Leeds Teaching Hospital NHS Trust
- 09.20 CEM data/technologies update**  
Dr Sarah Savaridas, University of Dundee
- 09.40 Assessment of the axilla**  
Miss Penny Moyle, Cambridge University Hospitals NHS Trust
- 10.00 Q&A panel discussion with speakers**

## SESSION 3 09.00 to 10.20

HALL 1C

### NURSING SESSION

Chairs: Mrs Sue Holcombe and Ms Simerjit Rai

- 09.00 Scoping the CNS workforce for the provision of psychological care**  
Ms Maria Noblet
- 09.20 Harmonisation of nursing and midwifery titles**  
Dr Victoria Harmer, Imperial College Healthcare NHS Trust
- 09.40 Breast nursing experience with the International Forum**  
Ms Lis Grimsey, East Sussex Healthcare NHS Trust  
Mrs Janet Hicks
- 10.00 Q&A panel discussion with speakers**

## SESSION 4 11.05 to 11.35

HALL 1A

### INVITED LECTURE

Chair: Mr Ashu Gandhi

- 11.05 Fertility and pregnancy during and after breast cancer**  
Prof Ann Partridge, Harvard Medical School

## SESSION 5 11.40 to 13.00

HALL 1A

### MANAGEMENT OF PREGNANCY ASSOCIATED BREAST CANCER

Chairs: Miss Karina Cox and Ms Kathryn Rigby

- 11.40 Diagnosis and surgery for women with Pregnancy Associated Breast Cancer**  
Mr Ashu Gandhi, Manchester University NHS Foundation Trust
- 12.00 Systemic therapy during pregnancy and in the postpartum**  
Dr Anne Armstrong, The Christie NHS Foundation Trust
- 12.20 Radiotherapy during pregnancy**  
Dr Samantha Nimallesena, Royal Marsden NHS Foundation Trust
- 12.40 Q&A panel discussion with speakers**

## SESSION 6 11.40 to 13.00

ROOM 3

### ABS & UKBCG GUIDANCE ON NACT

Chairs: Miss Julie Doughty and Prof Andreas Makris

- 11.40 NEST Trial Data**  
Mr Stuart McIntosh, Queen's University Belfast
- 11.50 Oncology – latest guidance**  
Prof Carlo Palmieri, University of Liverpool
- 12.05 Imaging patients pre & post NACT**  
Dr Sarah Vinnicombe, Gloucestershire Hospitals NHS Foundation Trust
- 12.15 Adjuvant radiotherapy post NACT**  
Prof Andreas Makris, Mount Vernon Cancer Centre
- 12.25 Surgery – latest guidance**  
Miss Tracey Irvine, Royal Surrey County Hospital
- 12.40 Q&A panel discussion with speakers**

**SESSION 7 11.40 to 13.00 HALL 1C**

**INNOVATION SESSION**

Chairs: Miss Shelley Potter and Mr Yazan Masannat

- 11.40 AI and breast imaging**  
Dr Richard Sidebottom, Royal Marsden NHS Foundation Trust
- 12.00 AI and digital health for breast surgery**  
Miss Nadine Hachach-Haram, Founder, Proximie
- 12.20 Innovation in digital consent**  
Mr Edward St John, Portsmouth Hospitals University NHS Trust
- 12.40 Q&A panel discussion with speakers**

**SPONSORED SYMPOSIUM 13.15 – 14.15 ROOM 3**

**HOW DO WE FOLLOW THE EVIDENCE FOR THE ONCOTYPE DX® TEST IN EARLY BREAST CANCER? PANEL DISCUSSION**

Mr Senthurun Mylvaganam, Royal Wolverhampton Hospitals NHS Trust, Mr Henry Cain, Newcastle Upon Tyne Hospitals NHS Trust, Miss Marianne Dillon, Swansea Bay University Health Board and Miss Clare Garnsey, Bolton NHS Foundation Trust

**EXACT SCIENCES**



A packed lunch will be served for delegates attending this session.

**SESSION 8 14.30 to 15.50 HALL 1A**

**ABS AUDITS SESSION**

Chairs: Mr Giles Cunnick and Mr Senthurun Mylvaganam

- 14.30 Screening data**  
Mr Ashu Gandhi, Manchester University NHS Foundation Trust
- 15.00 Screening Q&A**  
Mr Giles Cunnick, Buckinghamshire Hospitals NHS Trust
- 15.10 NABCOP Update**  
Prof Kieran Horgan, Leeds Teaching Hospitals
- 15.30 Q&A panel discussion with speakers**

**SESSION 9 14.30 to 15.50 ROOM 3**

**MANAGING ENDOCRINE SIDE EFFECTS**

Chairs: Mr Douglas Ferguson and Miss Charlotte Ives

- 14.30 Compliance with adjuvant endocrine therapy and management of side effects**  
Dr Ann Partridge, Harvard Medical School
- 14.50 Menopause care in breast cancer survivors**  
Miss Swati Jha, Sheffield Teaching Hospitals NHS Foundation Trust
- 15.10 Supporting women with adherence to endocrine therapy**  
Prof Linda Sharp, Newcastle University and Prof Eila Watson, Oxford Brookes University
- 15.30 Q&A panel discussion with speakers**

**SESSION 10 14.30 to 15.50 HALL 1C**

**PERSONALISATION OF BREAST CANCER CARE: EVIDENCE FOR NOW AND THE FUTURE**

Chairs: Prof Ramsey Cutress and Prof John Benson

- 14.30 Are randomised control trials leading or misleading us?**  
Dr David Dodwell, Nuffield Department of Population Health, University of Oxford
- 14.50 James Lind Alliance Priority Setting Partnership – setting research priorities for breast surgery**  
Mr Stuart McIntosh, Queen's University Belfast
- 15.10 Individual breast cancer genomic profiling for personalised cancer therapy**  
Dr Jean Abraham, Cambridge University Hospitals NHS Foundation Trust
- 15.30 Q&A panel discussion with speakers**

**SESSION 11 16.30 to 17.00 HALL 1A**

**INVITED LECTURE**

Chair: Miss Sarah Downey

- 16.30 Hunterian Lecture - Ethnicity And Breast Cancer In The UK**  
Miss Toral Gathani, Nuffield Department of Population Health, University of Oxford and Oxford University Hospitals NHS Foundation Trust

**SESSION 12 16.30 to 17.00 ROOM 3**

**MAMMARY FOLD POSTER PRIZE SESSION**

Chairs: Ms Natasha Jiwa and Ms Alex Humphreys

# Programme TUESDAY 17TH MAY

08.00 TO 09.00	REGISTRATION, WELCOME REFRESHMENTS, EXHIBITION AND POSTER VIEWING				
	HALL 1A	ROOM 3	HALL 1C		LIVE LOUNGE
09.00 TO 10.20	<b>SESSION 13</b> REDUCING BREAST CANCER INCIDENCE	<b>SESSION 14</b> RISK ADAPTIVE TREATMENT	<b>SESSION 15</b> PRIZE PAPERS SESSION		
10.25 TO 10.55	<b>SESSION 16</b> INVITED LECTURE: OPTIMISING SURGICAL DECISION MAKING FOR WOMEN AT ELEVATED BREAST CANCER RISK			10.25 TO 11.25	BREAST SURGERY & BREAST CANCER TREATMENT PAPERS SESSION
10.55 TO 11.30	REFRESHMENTS, EXHIBITION AND POSTER VIEWING IN HALL 2				
11.30 TO 12.50	<b>SESSION 17</b> ALTERNATIVE STRATEGIES TO MANAGE ONE STOP REFERRALS	<b>SESSION 18</b> DAY SURGERY	<b>SESSION 19</b> MAMMARY FOLD SESSION		
12.50 TO 14.10	LUNCH, EXHIBITION AND POSTER VIEWING IN HALL 2				
13.00 TO 14.00		<b>SPONSORED SYMPOSIUM</b> SIRIUS MEDICAL		13.00 TO 13.20	BREAST SURGERY & BREAST CANCER TREATMENT PAPERS Q&A SESSION WITH PRESENTERS
14.10 TO 14.40	<b>SESSION 20</b> INVITED LECTURE: THE IMPORTANCE OF BEAN COUNTING IN BREAST SURGERY – THE FUTURE OF CODING, TARIFF AND METRICS				
14.45 TO 16.05	<b>SESSION 21</b> EQUALITY, DIVERSITY AND WORKFORCE HEALTH IN THE NHS	<b>SESSION 22</b> OPTIMAL MANAGEMENT OF EARLY TRIPLE NEGATIVE BREAST CANCER	<b>SESSION 23</b> OLIGOMETASTATIC DISEASE		
16.05	CLOSE OF CONFERENCE				

**SESSION 13 09.00 to 10.20**

HALL 1A

**REDUCING BREAST CANCER INCIDENCE**

Chairs: Miss Jennifer Hu and Miss Nicola Roche

- 09.00 How can we reduce breast cancer incidence?**  
Prof Jack Cuzick, Wolfson Institute of Population Health, Queen Mary University of London
- 09.20 Genetic testing for all breast cancer**  
Prof Clare Turnbull, The Institute of Cancer Research
- 09.40 Patient engagement in lifestyle changes to reduce breast cancer risk**  
Mrs Rebekah Law, Royal Marsden NHS Foundation Trust
- 10.00 Q&A panel discussion with speakers**

**SESSION 14 09.00 to 10.20**

ROOM 3

**RISK ADAPTIVE TREATMENT**

Chairs: Mr Matthew Barber and Associate Professor Sue Down

- 09.00 Axillary node localisation techniques**  
Associate Professor Amit Goyal, University Hospitals of Derby and Burton NHS Foundation Trust
- 09.20 Her2 RADICAL**  
Dr Iain MacPherson, Beatson West of Scotland Cancer Centre
- 09.40 Risk adapted radiotherapy**  
Dr Indrani Bhattacharya, Addenbrooke's Hospital
- 10.00 Q&A panel discussion with speakers**

**SESSION 15 09.00 to 10.20**

HALL 1C

**PRIZE PAPER SESSION**

Chairs: Miss Rachel Bright-Thomas and Mr Baek Kim

- 09.00 Margin involvement in invasive breast cancer leads to increased distant recurrence after breast conservation: Systematic review**  
Dr James Bundred, Leeds Teaching Hospitals NHS Foundation Trust
- 09.10 Radiological prediction of axillary lymph node response following neoadjuvant chemotherapy - An aid to patient selection criteria for reducing axillary surgery**  
Ms Sabreen Elbakri, NHS Tayside
- 09.20 Patient-reported outcomes of prepectoral implant-based breast reconstruction: Early results from the Pre-BRA prospective multi-centre cohort study**  
Miss Kate Harvey, University of Bristol
- 09.30 Development of a trainee oncological breast surgery educational program, by trainees for trainees**  
Dr Hugh Lurcott, Epsom & St. Helier University Hospitals and Dr Kirakoula Georgas, Epsom & St. Helier University Hospitals
- 09.40 Systematic review of partial breast reconstruction with pedicled perforator artery flaps: Clinical, oncological and cosmetic outcomes**  
Mr Ojas Pujji, Morriston Hospital, Swansea
- 09.50 Therapeutic mammoplasty is associated with fewer long-term side-effects from breast radiotherapy**  
Mr Arjuna Brodie, University Hospitals of Leicester
- 10.00 No occult malignancy identified in 1130 transmale gender-affirming mastectomy specimens**  
Dr Brogan Rudge, North Manchester General Hospital
- 10.10 Discussion**

**SESSION 16 10.25 to 10.55**

HALL 1A

**INVITED LECTURE**

Chair: Prof Chris Holcombe

- 10.25 OPTIMISING SURGICAL DECISION MAKING FOR WOMEN AT ELEVATED BREAST CANCER RISK**  
Dr Stephanie Wong, Jewish General Hospital Segal Cancer Centre, McGill University

**SESSION 17 11.30 to 12.50**

HALL 1A

**ALTERNATIVE STRATEGIES TO MANAGE ONE STOP REFERRALS**

Chairs: Mr Pudhupalayam Bhaskar and Miss Carol-Ann Courtney

- 11.30 Mastalgia pathway: Derbyshire experience**  
Mr Mark Sibbering, University Hospitals of Derby and Burton
- 11.50 Online application for self-referral of patients**  
Mr Ahsan Rao, Broomfield Hospital
- 12.10 Direct access to breast clinics, the Yeovil experience**  
Miss Caroline Osborne, Yeovil District Hospital and Dorset County Hospitals Foundation Trusts
- 12.30 Q&A panel discussion with speakers**

**SESSION 18 11.30 to 12.50**

ROOM 3

**DAY SURGERY**

Chairs: Mr Sankaran Narayanan and Mr Ilyas Khattak

- 11.30 Facilitating day surgery for breast cancer**  
Miss Jo Marsden, British Association Of Day Surgery
- 11.50 Drainless implant reconstruction**  
Ms CJ Tolan, Royal Marsden NHS Foundation Trust
- 12.10 GIRFT data on length of stay**  
Miss Tracey Irvine, Royal Surrey County Hospital NHS Foundation Trust
- 12.30 Q&A panel discussion with speakers**

**SESSION 19 11.30 to 12.50**

HALL 1C

**MAMMARY FOLD SESSION**

Chairs: Ms Natasha Jiwa and Ms Alex Humphreys

- 11.30 Introduction and update from Mammary Fold**  
Ms Natasha Jiwa and Ms Alex Humphreys
- 11.40 Curriculum update**  
Ms Anne Tansley
- 12:05 Making the most of Breast Training Opportunities**  
Miss Rachel Bright-Thomas
- 12:30 Panel discussion - Trainees Q&A**  
Mrs Katy Hogben

**SPONSORED SYMPOSIUM 13.00 - 14.00**

ROOM 12

**SIRIUS PINTUITION POWERED BY GPSDETECT™  
PRACTICAL, WORKSHOP-BASED SYMPOSIUM**

- 13:05 Experience of Sirius Pintuition in UK and Q&A**  
Miss Leena Chagla, St Helens & Knowsley Teaching Hospitals NHS Trust
- 13:15 Global experience Sirius Pintuition & iBRANET and Q&A**  
Mr Edward St. John, Portsmouth Hospitals University NHS Trust
- 13:25 Introduction to Sirius Pintuition GPSDetect™**  
Chris Atkin, Sirius Medical
- 13:30 Hands on session with phantoms**  
Chris Atkin, Sirius Medical

This is a pre-registered session, a packed lunch will be served for delegates attending.

**SESSION 20 14.10 to 14.40**

HALL 1A

**INVITED LECTURE**

Chair: Miss Karina Cox

- 14.10 The importance of bean counting in breast surgery – the future of coding, tariff and metrics**  
Mr Ken Dunn, International Burn Injury Database

**SESSION 21 14.45 to 16.05**

HALL 1A

**EQUALITY, DIVERSITY AND WORKFORCE HEALTH IN THE NHS**

Chairs: Miss Leena Chagla &amp; Miss Lucy Khan

- 14.45 Burn out and psychological support for NHS staff**  
Dr Olivia Donnelly, North Bristol NHS Trust
- 15.05 Gender equality**  
Speaker tbc
- 15.25 Improving diversity within surgery**  
Baroness Helena Kennedy QC, IBHRI
- 15.45 Q&A panel discussion with speakers**

**SESSION 22 14.45 to 16.05**

ROOM 3

**OPTIMAL MANAGEMENT OF EARLY TRIPLE NEGATIVE BREAST CANCER**

Chairs: Miss Nicola Roche and Miss Isabella Dash

- 14.45 Breast conservation after neo-adjuvant chemotherapy for triple negative breast cancer**  
Dr Stephanie Wong, Jewish General Hospital Segal Cancer Centre, McGill University
- 15.05 Immunotherapy**  
Prof Peter Schmid, Bart's Cancer Institute
- 15.25 The role of PARP inhibitors**  
Prof Andrew Tutt, The Institute of Cancer Research
- 15.45 Q&A panel discussion with speakers**

**SESSION 23 14.45 to 16.05**

HALL 1C

**OLIGOMETASTATIC DISEASE**

Chairs: Mr Lazlo Romics and Dr Vassilis Pitsinis

- 14.45 Oligometastatic disease - is this a curable entity?**  
Prof Carlo Palmieri, University of Liverpool
- 15.05 SBRT for oligometastatic breast cancer**  
Dr Anna Kirby, Royal Marsden NHS Foundation Trust
- 15.25 Optimal imaging; role of PET/CT and WBMRI**  
Dr Bhupinder Sharma, The Royal Marsden Hospital & The Institute of Cancer Research
- 15.45 Q&A panel discussion with speakers**



# Programme

## SHORT PAPERS

All short paper and facilitated Q&A sessions will take place in the Live lounge located in the exhibition hall

### ONCOPLASTIC BREAST SURGERY ORAL PAPERS SESSION

#### MONDAY 16TH MAY

PRESENTATIONS 10.30 TO 11.30 FACILITATED LIVE Q&A WITH AUTHORS 13.15 TO 13.35

##### Chest wall perforator flaps for whole breast reconstruction – Feasibility

Peter Barry, Royal Marsden NHS Foundation Trust

##### PERforator flaps: Doctor needs in training and attitudes. The PERDITA Survey

Peter Barry, Royal Marsden NHS Foundation Trust

##### Cost of delayed versus immediate autologous breast reconstruction

Michael Boland, Imperial College Healthcare Trust

##### Long-term patient-reported outcomes of immediate breast reconstruction: Initial results from the Brighter Study

Shelley Potter, University of Bristol

##### Rates of revision and secondary reconstruction procedures 8 years following immediate breast reconstruction: Results from the Brighter long-term breast reconstruction outcome study

Shelley Potter, University of Bristol

##### Incorporation of Patient Reported Outcomes Measures (PROMs) in routine oncoplastic breast surgery service using the BREAST-Q and REDCap®

Saed Ramzi, University Hospitals Plymouth NHS Trust

### REFERRALS, DIAGNOSIS & SURVIVORSHIP PAPERS SESSION

#### MONDAY 16TH MAY

PRESENTATIONS 16.00 – 17.00 FACILITATED LIVE Q&A WITH AUTHORS 17.00 – 17.20

##### Efficient management of new patient referrals: Further data with increased numbers confirms the safety of advanced nurse practitioner (ANP) led telephone breast pain clinics

Katy Ellis, Manchester University Foundation Trust

##### Developing and testing a web-based intervention to support pain and symptom self-management in breast cancer surgery

Sue Hartup, Leeds Teaching Hospitals NHS Trust

##### Experiences and views of women undergoing BRCA genetic testing in the UK; A qualitative systematic review

Zeinab Hassanein, University of Nottingham

##### Preparing to survive: Improving outcomes for young women with breast cancer

Alison Hunter-Smith, TIG Fellow Liverpool

##### Exploring the nipple aspirate fluid microbiome in breast cancer patients

Natasha Jiwa, Imperial College Healthcare Trust

##### LYMPHA for primary prevention of breast cancer related lymphedema - Prospective observational study

Ashwin Rajagopal, Manipal Hospital, Bangalore, India

##### Developing an effective triaging algorithm for breast referrals

Laura Smith, James Paget University Hospital

### BREAST SURGERY & BREAST CANCER TREATMENT PAPERS SESSION

#### TUESDAY 17TH MAY

PRESENTATIONS 10.25 – 11.25 FACILITATED LIVE Q&A WITH AUTHORS 13.00 – 13.20

##### 3-dimensional intraoperative analysis of screen detected breast malignancies reduces re-excision rates

Jo Mondani, Aberdeen Royal infirmary

##### Are sentinel lymph node biopsies necessary in older breast cancer patients - Should we be "choosing wisely"?

Alison Luther, University Hospital Southampton

##### Impact of radiation treatment on immediate direct to implant reconstruction with ADM

John Mathew, North West Anglia NHS Foundation Trust

##### Does the association between survival and receipt of post-mastectomy radiotherapy vary by age at diagnosis among women with early invasive breast cancer?

Katie Miller, Clinical Effectiveness Unit, Royal College of Surgeons of England

##### Are supero-lateral group of nodes affected in axilla in breast cancer? A validation study

Diptendra Kumar Sarkar, Breast Service, IPGIMER & SSKM Hospitals, India

##### VTE prophylaxis in breast surgery: Clinical audit of over 5000 patients evaluating a local protocol

Ryo Yoshimura, York and Scarborough Teaching Hospitals NHS Foundation Trust

##### Predictors of axillary pathologic complete response following neoadjuvant chemotherapy for node positive breast cancer

Alexandra Zaborowski, St Vincent's University Hospital, Ireland

# General information

#### ABS CONFERENCE APP

The ABS Conference App can be downloaded from your app store. It includes programme information, a 'my schedule' facility, speaker information, delegate list and exhibitors list. You can also view the abstracts and electronic posters via the Conference App.

#### CLOAKROOM

There is a cloakroom for general use on the ground floor of the ACC. Additional space will be made available for luggage on Tuesday. The cloakrooms are always attended by a member of ACC staff; please note, however, that items are left at your own risk.

#### CONFERENCE SESSIONS

Conference sessions will take place on the Upper Level of the ACC and can be accessed via the escalators or lift.

#### CPD

The Association of Surgeons of Great Britain and Ireland have awarded 5 points per day for this two-day conference. Delegates will be e-mailed after the conference with information about how to download their certificate of attendance from the ABS website.

#### DELEGATE LIST

A delegate list is available on the conference app. This includes the names of delegates who have consented to have their details uploaded. Other delegates can add their details during the conference by clicking on the Delegate List Registration tab on the app. The password for delegates to access the delegate list is: Liverpool2022

#### EMERGENCIES

In the event of an emergency please contact a member of staff from Profile Productions, ABS, or a member of the ACC security staff, who you will see throughout the building. In all other instances, please dial 999.

#### EVALUATION

An online evaluation form will be sent to all delegates after the conference. We would welcome your feedback on this event.

#### FEEDING ROOM

Organiser's Room 1, located on the Ground Floor of the ACC can be used as a quiet space for feeding. Please ask at the Registration desk should you wish to access this room.

#### LIVE LOUNGE

Located in the Exhibition Hall the Live lounge will offer delegates the chance to listen in to session from Hall 1A as well as attend the oral paper sessions. The oral paper sessions will also include a facilitated Q&A with the authors. Please see the full oral paper sessions programme on page 8

#### LUNCH AND REFRESHMENTS

These will be served in the Exhibition Hall, Hall 2, on the Lower Ground Floor at the times shown in this programme.

#### PHOTOGRAPHY

A photographer will be taking images of the conference during the event for use by the ABS in future publications and on the website. If you do not wish to be included in any of these, please speak to a member of the team at the Registration desk and you will be given a different coloured lanyard to avoid inclusion in any photographs.

#### PRAYER ROOM

Organiser's Room 2, located on the Ground Floor of the ACC is available as a quiet space for prayer. Please ask at the Registration desk should you wish to access this room.

#### SPEAKER PREVIEW

A speaker preview room is available for all speakers, located in Room 10 on the Upper Level of the ACC, please ensure that you hand-in, or check your presentations with the technical team.

#### REGISTRATION

Registration will be open in ACC Foyer at the following times:  
Monday 16th May 07:45 to 19:30  
Tuesday 17th May 07:45 to 16:30

#### TWITTER AND SOCIAL MEDIA

Delegates are strongly encouraged to Tweet ideas, debate and chat or to send comments at #ABSCONF22 during the conference.

#### WEBCASTS

Webcasts of most of the presentations will be available in due course on the ABS website for members to view.

#### WI-FI

Delegates can use the free venue wi-fi. Log on to ACC wi-fi network for access.

#### Q&A IN HALL 1A

Delegates wishing to ask a question Hall 1A can do so via slido.

Please go to <https://www.sli.do> and type in the event code ABSCONF22 or alternatively scan this QR code.



#### POSTER SESSIONS

The electronic posters will be available to browse throughout the conference in the Exhibition Hall, Hall 2, on large screens and via the app.

#### SOCIAL EVENTS

##### POSTER VIEWING

There will be an additional poster viewing session in the Exhibition Hall, Hall 2 on Monday 16th May from 17.00 – 18.45

##### ANNUAL DINNER

The ABS Annual Dinner will take place at the Rum Warehouse, part of the Titanic Hotel in Liverpool with a welcome reception starting at 7.30pm for an 8pm dinner. Attendees must have bought a ticket in advance to attend the dinner. The dress code is lounge suits.

Coaches will depart from the ACC Liverpool from the Lower Riverside between 7.00pm and 7.25pm

A Taxi Marshal and hotel staff will be available to assist guests to call a taxi after the dinner and Uber taxis are also readily available in Liverpool.

HOLOGIC®



## Diagnose & treat more efficiently

### Image specimens in theatre

#### Faxitron™ Trident® HD Specimen Radiography System

- Active imaging detector size of 16x18cm
- Instant sample verification
- Faster procedure completion time

Faxitron™  
**Trident® HD**  
Specimen Radiography System

### Easily locate breast lesions

#### LOCALIZER™ Wire-Free Guidance System

- RFID tag implantable anytime prior to surgery
- Real time localization with mm precision
- Single use probe, supports infection control

**LOCALIZER™**  
Wire-free Guidance System

Book your demo today: [www.hologicbreastsurgery.com/eur](http://www.hologicbreastsurgery.com/eur)

ADS-03235-GBR-EN Rev. 001 ©2021 Hologic, Inc. All rights reserved. Hologic, Faxitron, LOCALIZER, Trident, The Science of Sure and associated logos are trademarks or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks and product names are the property of their respective owners. This information is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshow, it is not always possible to control where such materials appear. For information on specific products available for sale in a particular country, please contact your Hologic representative or write to [euinfo@hologic.com](mailto:euinfo@hologic.com)

# Trade Exhibition

The trade exhibition will be open in Hall 2 at the following times

Monday 16th May 08:00 to 18:45

Tuesday 17th May 08:00 to 14:10

**3D** 3-D MATRIX  
MEDICAL TECHNOLOGY

STAND 43

3-D Matrix is a leading medical device company, which optimises MIT-founded, self-assembling peptide technology to continually innovate and serve healthcare professionals around the globe. The company is headquartered in Tokyo, Japan and has since expanded with offices now across Europe, North America and Asia and a global network of partners and distributors. Its flagship product is the haemostatic hydrogel, PuraBond which is made of up synthetic peptides in a pre-filled syringe. PuraBond utilises its unique ready-to-use, transparent properties to improve bleeding management during surgery.

**3M** Science.  
Applied to Life.™

STAND 46

3M, with the acquisition of KCI, focuses on providing better care through patient-centred science. Helping transform patient outcomes by reducing the risk of preventable complications. From solutions for BSI and SSI risk reduction, to helping reduce bioburden to help minimize infection, to vital sign monitoring and temperature management, our team is ready to partner with you to strive toward a world with zero complications.

amoena

STAND 30

• Recovery Care • Breast forms and shapers • Breast care apparel

Established in 1975, Amoena is the world's leading breast care brand. As the industry pioneer, Amoena is dedicated to supporting women's confidence to live an active life after breast cancer. The company's products combine technology with supreme comfort in an extensive range of bras, swimwear and breast symmetry products designed to support a woman through every stage of her breast cancer journey. Recovery starts in the operating theatre, and Amoena's Recovery Care products help ensure the best surgical result and utmost comfort as the wound heals, with post-operative bras, scar therapy and compression garments for the weeks immediately after surgery. The right prosthesis restores not just a woman's outline but also her posture and self-image. Amoena's innovative breast forms include the award-winning Adapt Air with its integral air chamber that allows the wearer to achieve just the right volume and fit.

AstraZeneca

STAND 42

AstraZeneca has provided a sponsorship grant towards the independent Association of Breast Surgery Conference 2022. AstraZeneca have not had any involvement in the meeting arrangements or content. AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca is based in five different locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. For more information, please visit [www.astrazeneca.co.uk](http://www.astrazeneca.co.uk) and follow us on Twitter @AstraZenecaUK.





Roche has been advancing breast cancer research for more than 30 years.

We have always believed a personalised approach provides patients with the best possible outcomes and we continue to look for ways to reduce the impact of breast cancer on patients' quality of life.

M-GB-00006725 / March 2022

Roche Products Limited has provided financial support for the organisation of this educational meeting but has had no control over the content.

Roche has provided financial support to exhibit at this meeting.



STAND 28

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD UK leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes.



STAND 25

We're Breast Cancer Now, the research and care charity. We're here for anyone affected by breast cancer, the whole way through, providing support for today and hope for the future. We're that trusted friend to turn to for caring support when you need it. The expert authority on breast cancer research who is making breakthroughs and driving forward progress. And a vehicle for change, acting now to make sure anyone affected by breast cancer gets the best possible treatment and care. We believe that we can change the future of breast cancer and make sure that, by 2050, everyone diagnosed with the disease lives – and is supported to live well. But we need to act now.



STAND 47

Check4Cancer, has managed over 15,000 insured and self-pay patients in our award-winning OneStop breast cancer diagnostic pathway by working with ABS surgeons who provide a best practice service. With a rapidly expanding referral base from AXA, Cigna, Vitality, WPA and the self-pay market, we are now looking to recruit more breast surgeons to grow our network of private diagnostic OneStop Breast clinics. Drop by our stand to hear how to join our diagnostic network or use our new breast cancer genetic service, relocated to a UK laboratory with mainstream referral and post-test counselling for patients with a mutation.



STAND 5

Cirdan is a leading provider of informatics and imaging solutions that support and speed up patient diagnosis. Headquartered in the UK, with offices in Canada and Australia, Cirdan is recognised as one of the leading suppliers of laboratory information systems (LIS) worldwide. Our products include ULTRA, a LIS that supports and streamlines the operations of a clinical laboratory, and the CoreLite and Solas-OR x-ray systems which expedite breast cancer diagnosis. We also offer Tutor, a digital pathology education platform, and software solutions that support artificial intelligence and machine learning in digital pathology technologies. Find out more at [www.cirdan.com](http://www.cirdan.com).



STAND 40


CoppaFeel! are a breast cancer awareness and education charity. We exist to educate, empower and encourage young people to get to know their bodies, in order to stamp out late detection of breast cancer. We want to establish breast awareness as a public health priority, so we support healthcare professionals with health promotion by providing patient information materials and continuing professional development resources, such as our new online learning module for Medical Students.




STAND 3


The East Midlands Mastalgia Pathway Implementation Team is a group of NHS professionals who have developed and implemented a mastalgia pathway within primary care which is already seeing widespread adoption. The Team has been working strenuously to support the implementation of these primary care breast pain clinics throughout the NHS and help spread the adoption at scale and pace. For further information please contact Mark Sibbering at [mark.sibbering@nhs.net](mailto:mark.sibbering@nhs.net) or John Robertson at [john.robertson@nottingham.ac.uk](mailto:john.robertson@nottingham.ac.uk).









TRANSPARENT



SYNTHETIC









READY-TO-USE




EASY TO APPLY

Come and see us on Booth 43

 @3dmatrixEMEA  
 3-D Matrix EMEA  
 @3dm\_emea

 3-D Matrix EMEA  
 www.3dmatrix.com  
 infoeu@puramatrix.com



PuraBond

Absorbable Haemostat

**3-D Matrix Europe SAS**  
 11 Chemin des Petites Broses  
 69300 Caluire-et-Cuire-FRANCE  
 Tel: +33 (0)4 27 19 03 40  
 infoeu@puramatrix.com  
 www.3dmatrix.com

Please read carefully the instructions for use. PuraBond IFU-009 Rev 2. PuraBond is a class III medical device, CE marked according to European council directive 93/42/EEC on medical devices and its relatives.

**CE** 2797 **BSI**

FY 0TH 001 EU EN v1 2022 03 15



## STAND 44

Elemental Healthcare Ltd are a leading UK distributor. Part of the Surgical Innovations PLC group, for over 30 years we have been at the forefront of delivering surgical innovation at a cost attainable price point. Through a partnership approach with Meccellis Biotech, an expert in Tissue and Cell engineering, our Cellis® breast acellular dermal matrix range is designed to reinforce soft tissue during breast reconstruction. Freeze dried and free from preservatives, the innovative breast pocket and Cellis® meshed are designed for sub and pre pectoral reconstruction. T: 0844 412 0020 E: info@elementalhealthcare.co.uk W: www.elementalhealthcare.co.uk  
 Twitter: @ElementalHCare LinkedIn: linkedin.com/company/elemental-healthcare-ltd



## STAND 32

At Endomag, we believe everyone deserves access to a better standard of cancer care. Many of the UK's leading physicians and hospitals use our technologies to help women avoid breast surgery when it isn't needed, and experience better outcomes when it is. Our Sentimag® localisation system works alongside the Magseed® marker and Magtrace® lymphatic tracer to deliver non-radioactive tissue localisation and sentinel node biopsy procedures with pinpoint accuracy. To date, the Sentimag® platform has now helped over 200,000 patients access the best possible breast care, across more than 45 countries and six continents. Join the magnetic revolution today.



## STAND 2

**Eurosurgical:** We are a family run UK surgical distribution company for manufacturers of reconstructive, breast and plastic surgery devices. Our focus is sourcing and bringing high quality, innovative products to the market. We are pleased to represent; TIGR Matrix for breast surgery, Retralight single use lighted retractor with smoke evacuation, Duramesh - the world's first mesh suture, Prima electrosurgery products including smoke evacuation finger-switches and all tips, a full range of liposuction and fat grafting equipment including the new St'Rim kits and Lipocube for nano-fat transfer as well as post post-surgical support garments.



## STAND 34

Exact Sciences is a leading, global cancer diagnostics company with over 6,500 employees worldwide. Our common aim is to eradicate cancer - and the suffering it causes - with tests that help in preventing cancer, detecting it earlier, and guiding treatment to provide life-changing value to patients. Building on the success of the Oncotype DX® and the Cologuard® tests, Exact Sciences is investing in its product pipeline to support patients before and throughout their cancer diagnosis and treatment. We serve patients in more than 90 countries and are rapidly building an even stronger international business to bring our tests to patients around the world. For more information on Exact Sciences, please visit the company's website ([www.exactsciences.com/uk](http://www.exactsciences.com/uk)) and follow us on Twitter (@ExactSciences), Facebook or LinkedIn (Exact-sciences). To learn more about the Oncotype DX test, please visit the product website ([www.oncotypeiq.com/en-GB/breast-cancer/healthcare-professionals/oncotype-dx-breast-recurrence-score/about-the-test](http://www.oncotypeiq.com/en-GB/breast-cancer/healthcare-professionals/oncotype-dx-breast-recurrence-score/about-the-test)) or phone us on 020 3031 8087.



## STAND 23

FaHRAS is a sophisticated evidence-based software system that enables the user to build and store a family history, however simple or complex, and run a variety of analyses against their family history to quantify their risk of developing breast cancer in an objective, efficient manner. FaHRAS is available for both Primary Care and Secondary Care.  
**FaHRAS for Primary Care**  
 The NICE Guidelines (CG164) – used in primary care breast pain clinics  
**FaHRAS-Secondary Care**  
 The NICE Guidelines (CG164), IBIS (Tyrrer-Cuzick), Canrisk, and Manchester Risk Assessment Models – used in specialist setting  
 Please enquire for more details at <http://www.fahras.co.uk/> or call us at 08452244248.

## CURASUPPORT COMPRESSION & SCAR THERAPY

### The best possible aftercare for your patients

Following any type of breast surgery, your patients need the best possible aftercare – from the recovery room all the way through the initial weeks following surgery.

As the world's leading breast care brand, Amoena's post-surgery range offers the very best in care and comfort. It includes:


- **Compression bras, belts and vests** to support wound healing after surgery
- **Silicone scar patches** to minimise the risk of excessive scarring
- **Post-surgical scar compression garments** to accelerate the healing process

Plus sports-style leisure bras to help restore a feeling of normality during the later stages of healing.

See Amoena's full range of **compression bras, recovery care products, silicone breast forms and enhancers** at [www.amoena.co.uk](http://www.amoena.co.uk) or visit us at **stand 30**.



Stand 30



Compression Bras



Silicone Scar Patches



Compression Garments



# Come and meet the AstraZeneca Medical Affairs Team at Stand 42



AstraZeneca has provided a sponsorship grant towards the independent Association of Breast Surgery Conference 2022. AstraZeneca have not had any involvement in the meeting arrangements or content.  
GB-35403 | March 2022



[bd.com/en-uk](http://bd.com/en-uk)



## BD are attending Association of Breast Surgery Congress 16/17<sup>th</sup> May in Liverpool

How can our products support your care practices – now and tomorrow

Come and speak to the team about our full range of infection prevention products and our haemostatic range to help manage bleeding in breast surgery.

### Infection prevention



BD Surgical Clipper



BD Surgical Skin Marker



BD ClipVac™

### Haemostats



BD Arista™



BD Avitene™



Skin preparation



BD, the BD Logo, Arista, Avitene, Progel and ClipVac are trademarks of Becton, Dickinson and Company or its affiliates. © 2022 BD. All rights reserved. (BD-56075, March 2022)



## STAND 45

Flat Friends UK is dedicated to supporting women who have had single or double mastectomy surgery without breast reconstruction, including those who may face such decisions now or in the future, due to either a breast cancer diagnosis or preventative surgery. We believe living without reconstruction is a positive outcome.



## STAND 14

GC Aesthetics® is an established global medical device company focused on Aesthetic and Reconstructive surgery. GCA® is passionate and committed to women's breast health and safety through the most comprehensive breast implant portfolio with systems in place to ensure the safety of our products through pre-clinical testing, clinical studies and excellent global post market surveillance. GCA® is committed and focused on quality, safety and reliability. With more than 40 years of experience and more than 3 million implants fitted during the last 10 years. Surgeons and patients across 70 countries have trusted GCA® products, which are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness. For further information about GC Aesthetics® Breast Implants or any other GCA® products, please visit booth 14 today or visit website: [gcaesthetics.com](http://gcaesthetics.com).



## STAND 11

"Creating the Future of Oncology, for People with Cancer"

Gilead Sciences Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with a goal of creating a healthier future for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has approved products for both haematological malignancies and solid tumours and an extensive clinical development programme covering many different cancer types"



## STAND 39

Healthcare 21 are delighted to be a Corporate Sponsor of ABS 2022. On display at our stand this meeting we have:

ARTIA™ and new ARTIA PRE-PEC™; an ADM that is deliberately designed to optimize breast reconstructive surgery outcomes.

REVOLVE™ Fat Processing System

STRATTICE™ Reconstructive Tissue Matrix

KELLER FUNNEL 2™ - Breast Implant Delivery Sleeve

Healthcare 21 are the exclusive sales and marketing partner for these Allergan Aesthetics™ products in the UK. We look forward to meeting you and introducing our surgical product portfolio.



## STAND 19

Hologic® is an innovative medical technology company that enables healthier lives everywhere, every day.

We are also a company that prospers and grows, which is why we've been able to expand our offerings to empower even more people and champion women's health. What powers our growth across Breast & Skeletal Health, Diagnostics and GYN Surgical is also what differentiates us: the exceptional and clinically proven capacity of our products to detect, diagnose and treat illnesses and other health conditions earlier and better. This clinical superiority creates high expectations, which we fulfil by continually challenging ourselves to improve health through better technology, education and market access. The world leader in mammography, Hologic has expanded its product portfolio significantly through insight-driven innovation and strategic acquisitions to address the entire clinical continuum of breast cancer diagnosis and care. From digital specimen radiography and stereotactic breast biopsy systems, to breast biopsy markers and surgical guidance systems. Hologic's comprehensive suite of products is designed to meet the unmet and changing needs of patients and clinicians.





## Localisation and staging, together in one platform

Get greater flexibility and precision during breast surgery with our magnetic surgical guidance system.

Sentimag® lets you localise lesions, mark previously-positive nodes and perform sentinel node biopsies without wires or radioactive tracers.

Discover more at [endomag.com](http://endomag.com)



# PURSUING EARLIER DETECTION AND LIFE-CHANGING ANSWERS

From earlier cancer detection to treatment guidance, Exact Sciences is helping people face their most challenging decisions with confidence.

[www.exactsciences.com/uk](http://www.exactsciences.com/uk)  
[www.oncotypeiq.co.uk](http://www.oncotypeiq.co.uk)



Oncotype IQ is a registered trademark of Genomic Health, Inc. Exact Sciences is a registered trademark of Exact Sciences Corporation. © 2022 Exact Sciences Corporation. All rights reserved. EXS13475\_0322\_EN\_UK



### STAND 38

Ideal Medical Solutions Ltd are the UK distributor for the latest innovation in PrePec Breast Reconstruction, Exaflex. Minimise implant exposure to 60 seconds. In addition, we provide an extensive, high-quality range of all clinical specialties across various indications in both the NHS and the Private sector. Please visit our stand to find out further information on these clinically proven products: ONETRAC single-use retractor with built-in light source, Filtron Fat Transfer system, THOR diathermy blades, I.C Medical Smoke evacuation equipment, EZ Fan breast implant funnel and full range of single use cannulas, single use Forceps, and our full ENT range.



### STAND 35

At IGEA we study the clinical application of physical stimuli to biological systems. IGEA is the leading company for Electrochemotherapy, a minimally invasive treatment combining a low dose of a chemotherapy drug and an electrical pulse (electroporation) applied directly to the cancer cells using specific multiple, or individual needle electrodes. Our mission is to improve patients' Quality of Life by developing and producing innovative, effective and safe therapeutic systems for clinical practice.



### STAND 33

Independent Cancer Patient's Voice is a patient-led charity that aims to bring an effective independent patient voice into research. We involve patients in clinical research (including clinical trials, working with clinical/academic units, tissue banks etc). We believe that clinical research is improved by patients being partners with clinicians and healthcare professionals, rather than passive recipients of healthcare. To enable patients to do this, we run study days where cancer patients meet academics and clinicians who work in cancer research, and also the VOICE:Science for Patient Advocates course.



### STAND 1

Knitted Knockers UK is a charity that provides bespoke knitted or crochet breast prostheses for women that have undergone a mastectomy or lumpectomy. At KKUK, we want women to know that there is a lightweight, adjustable 100% cotton alternative to the silicone prostheses available. It takes the form of a real breast and is soft against the skin and is breathable. Our Aqua Knockers (100% acrylic) are also popular & allow ladies to swim or exercise with confidence. Each Knocker is Made with love and filled with hope, and we provide them FREE OF CHARGE to those who need them.




### STAND 20

A global healthcare leader uniting caring with discovery to deliver innovative medicines. Whether it's treating rare tumour types, leveraging precision medicine or discovering new ways to advance existing treatments, we're dedicated to making greater differences in lives of people living with cancer. To learn more, please visit [www.lilly.co.uk](http://www.lilly.co.uk).



### STAND 24

Founded in 1987, Merit Medical Systems, Inc. is a leading manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Our Merit Oncology is the new standard of care in wireless localization. We help healthcare providers achieve better patient outcomes through clinical and cost-effective care and drive progress through innovation, knowledge sharing and the latest scientific research. The SCOUT® Radar Localization system has been clinically demonstrated to drive value and improve patient outcomes. SCOUT is proven to improve radiology workflow and significantly reduce OR delays. This can mean more successful surgeries, optimized breast conservation strategies, and enhanced outcomes for women. Discover our portfolio and instructions for use at <https://www.merit.com/merit-oncology/>



Aesthetics and safety go hand in hand.

Let's keep innovation blooming.

Motiva Flora®

Learn more at [motiva.health](https://motiva.health)



STAND 37

MENTOR® was founded in 1969 and has a long, proud history in breast aesthetics, rooted in a commitment to high-quality breast implants and science-based innovations. We've maintained high standards of design, testing and safety, and we've earned the respect of the breast aesthetics community worldwide. Being a part of the Johnson & Johnson Family of Companies, we aspire to be the most trusted partner in breast aesthetics. By providing a broad range of products and clinical-based solutions we aim to help women maintain, enhance, and restore self-esteem and quality of life, whether that be breast reconstruction or for cosmetic reasons.



STAND 36

With our vision, our company is changing the breast aesthetics industry by designing, developing, and manufacturing a safe and innovative portfolio of silicone gel-filled breast implants, branded as Motiva®. At Motiva® We stand by the independence of today's women, and the evolution of beauty through cutting-edge technology and international quality standards. Motiva Implants® are proudly produced at two MDSAP-certified, state-of-the-art manufacturing facilities in Costa Rica and approved for sale in more than 80 countries. From its humble beginnings building prototypes in pizza ovens to listing on the Nasdaq Stock Market, the company has grown rapidly and expanded its product and technologies portfolio beyond implants to include such innovative solutions as the Divina® 3D simulating system, and MotivaImagine® Centers and surgical tools.

Connect with us

Email: [motivaedgeevents@establishmentlabs.com](mailto:motivaedgeevents@establishmentlabs.com)

Website: <https://motiva.health/>

Facebook: <https://www.facebook.com/motivaimplants>

Instagram: [https://www.instagram.com/motiva\\_uk/](https://www.instagram.com/motiva_uk/)

Linkedin: <https://www.linkedin.com/company/9432963>



STAND 31

The National Audit of Breast Cancer in Older Patients (NABCOP), commissioned by the Healthcare Quality Improvement Partnership, evaluates the care received by older women (aged 70+ years) diagnosed with breast cancer in NHS hospitals within England and Wales. NABCOP's 2022 Annual Report describes the process and outcomes of care for women, diagnosed with breast cancer between 1 January 2014 and 31 December 2020. Patterns for older women are compared to those for women aged 50–69 years. We also distinguish between the groupings: ductal carcinoma in situ; early invasive breast cancer; metastatic breast cancer. For further information, please visit: [www.nabcop.org.uk](http://www.nabcop.org.uk)

Nicola Jane

STAND 9

As the UK's leading mastectomy and post-surgery wear specialists we offer the widest selection of pocketed mastectomy bras, swimwear and breast forms. Expertly designed with comfort, security and fit in mind, our collection can be worn after all types of breast surgery including mastectomy, partial mastectomy, lumpectomy and reconstruction. Established in 1984 our small, family-run business has been helping to rebuild our customers' confidence and restore femininity for the past 38 years and there is nothing more important to us than helping you find what you are looking for.



STAND 13

One company, the complete portfolio, a total solution... we have you covered. Biocompatibility, strength and predictability at your fingertips. pfm medical have always led the evolution of surgical implants to meet the needs of breast reconstruction patients. Developed over 45 years, our pioneering surgical implants and complete synthetic and biological portfolio will meet all your surgical requirements. As a family business we are proud to manufacture our products in Germany, using cutting edge, proven, scientific processes to produce ethically sourced implants with optimum reliability. We are a trusted, global, healthcare partner with over 50,000 implants implanted worldwide. We are always pushing to develop high quality solutions for your demanding surgical needs. Our mission is to always improve the quality of life and quality of work for our customers and their patients.

# CAN YOUR LOCALISATION BE EFFECTIVE WITH MRI?

CHOOSE WISELY. CHOOSE SCOUT®

**NO SIGNIFICANT ARTIFACT** on MRI<sup>1</sup>

MRI Artifact Comparison<sup>2</sup>

SCOUT Reflector

RFID Tag

Magnetic Seed



Signal void artifacts in non-contrast T1 non-fat-saturated MR sequences.

1. Kefah Makbel et al. Reflector-guided Localization of Non-palpable Breast Lesions: The First Reported European Evaluation of the SAVI SCOUT® System. *Anticancer Research* 40: (2020).  
 2. Hayes MK. Update on Preoperative Breast Localization. *Radial Clin N Am* (2017); 591–603.







A Confident Choice for Life™



GC Aesthetics® is an established global medical device company focused on Aesthetic and Reconstructive surgery. GCA® is passionate and committed to woman's health and safety through a broad breast implant portfolio<sup>1</sup> with systems in place to ensure the safety of our products through pre-clinical testing, clinical studies and excellent global post-market surveillance<sup>2</sup>.

GCA® is committed and focused on quality, safety and reliability. With more than 40 years of experience and more than 3 million implants fitted during the last 10 years<sup>3</sup> Surgeons and patients across 70 countries have trusted GCA® products, which are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness<sup>4</sup>.


For further information about GC Aesthetics® Gel Breast Implants or any other GCA® products, visit our website: [gcaesthetics.com](http://gcaesthetics.com) and follow us on our social media platforms.

Email: [info@gcaesthetics.com](mailto:info@gcaesthetics.com)



1. Data on file, GC Aesthetics®, GCA catalogue, 2021  
2. Data on file, GC Aesthetics®, 2020  
3. Data on file, GC Aesthetics®, Countries Sales Report, 2021.  
4. Duteille F, et al. Ten-Year Safety Data for Eurosilicone's Round and Anatomical Silicone Gel Breast Implants. Aesthet Surg J Open Forum. 2019;1(2): o2012. Published 2019 Apr 27.

460-047



titanized




**TILOOP® Bra**  
Sub-Pectoral Breast Reconstruction

titanized



**TILOOP® Bra Pocket**  
Pre-Pectoral Breast Reconstruction or Augmentation

titanized



**TILOOP® Bra MPX**  
Mastopexy, symmetrical alignment or reduction surgery




TISSUE MATRICES



**Fortiva® 1.0 Perforated**  
Tissue Matrix



**Tutomesh®**  
Tissue Matrix



**Fortiva® 1.0**  
Tissue Matrix



Quality and Experience

Providing solutions in Breast Surgery Total Coverage

- › Ibbot
- › Mastopexy
- › Reduction
- › Pre & Sub Pectoral Reconstruction

[www.pfmmedical.co.uk](http://www.pfmmedical.co.uk)



### STAND 10

Q Medical Technologies Ltd is an independent UK company founded in 2004, based in Cumbria. As an organisation we are committed to the supply of products that provide benefits for patients, clinicians, and hospitals. We distribute and market a range of medical devices including SurgiMend® Acellular Dermal Matrix, POLYTECH breast & body contouring implants, B Lite lightweight breast implants, Ellman Radio Frequency technology and AccuVein AV500; a unique vein visualisation device for locating veins even in the most difficult patients. We offer representative coverage and on-site clinical training across the whole of the UK and Ireland.



### STAND 7

Raise Healthcare is a UK based Specialist Medical Device Distributor providing high quality solutions to the healthcare industry. We are the proud, exclusive supplier of Braxon® and Braxon Fast®, the world's first pre-shaped porcine acellular dermal matrix (ADM) for Pre-Pectoral Breast Reconstruction. With over 8,000 procedures performed in the UK, Braxon Fast® is an established, viable option supported by iBAG; the largest multi-centre PPBR study ever plus over 30 clinical publications from the UK and Europe. We are a progressive Company, who place value on strong customer relations. Based upon the core principles of delivering the highest quality products; proven by strong clinical evidence; supported by first-class professional education and a commitment to cost conscious pricing. Customer service: [enquiries@raisehealthcare.co.uk](mailto:enquiries@raisehealthcare.co.uk)



### STAND 15

#OptimisingBreastRecon As a distribution business we are dedicated to helping you solve your everyday challenges in breast reconstruction, burns, wound healing and tissue regeneration. We do this by bringing you together with innovative manufacturers, a partnership that provides excellent standards of service delivered in an ethical, responsive, flexible and straight forward manner which is focused on you and your patients.



### STAND 29

RPS Service is the UK and Ireland representatives for CompAI a leading manufacturer of innovative solutions for digital specimen radiography. The TrueView designed for surgical radiography enabling a surgeon to accurately determine margin assessment within 10 seconds minimising the risk of re-excision and saving at least 20 minutes per procedure. RPS Service can also service all makes of Digital Specimen Radiography deemed to be End of Life. As well all older models of analogue x-ray cabinets used for a wide range of applications. Web: [www.rpsservice.co.uk](http://www.rpsservice.co.uk) Email [info@rpsservice.co.uk](mailto:info@rpsservice.co.uk) Tel: 01932 550 137



### STAND 18


Roche is a pioneer in pharmaceuticals and diagnostics, focused on advancing science to improve people's lives. We have created truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. In the UK we employ over 2,000 people who work hard every day to bring our medicines and diagnostics to people who urgently need them. We work from bench to bedside - researching new medicines and diagnostics, running global clinical trials, and collaborating with the NHS to try to ensure rapid uptake and delivery of our products and services. For more information: [www.roche.co.uk](http://www.roche.co.uk)

**VISIT US ON STAND 15**



**Bioshield Pocket**

**Natural strength and rapid integration with sutureless placement**



- **Innovative design:** ultra thin, strong and easy to use
- **Quick** to prepare, place and position
- **Bioshield grip** a natural anchoring effect

**#OPTIMISINGBREASTRECON**  
OUTCOMES THROUGH SERVICE, INNOVATION AND SIMPLICITY

W: [www.regenmedical.co.uk](http://www.regenmedical.co.uk) T: 01793 575 050

Scan QR for video:



**STAND 49**

SamanTree Medical has developed a breakthrough medical imaging modality that enables new medical procedures with the will to improve cancer treatment. The Histolog® Scanner is a CE mark product since 2016 for high resolution imaging of the surface of fresh tissue. It is based on a novel ultra-fast confocal microscopy technology invented in EPFL in 2010. This innovation finds its application along the patient journey, from biopsy taking to surgical diagnostics.

**sanofi**

**STAND 21**

We recognise the burden that breast cancer places on individuals and the people who care for them. Their stories motivate and inspire us in our mission to develop novel treatment options, expand access to therapies, provide patient support services, and partner with patient organisations. This enables us to understand the needs of patients, their caregivers, as well as the healthcare professionals who treat them. MAT-XU-2200966 (v1.0) | Date of Preparation: April 2022



**STAND 17**

Sebbin is a Paris-based manufacturer of high-quality medical devices. Manufacturing our own implants gives us complete control over our quality and safety which means that when you choose a Sebbin implant you can trust that you are assuring your patients of the best standard of care. We offer a bespoke range of high-quality breast prostheses. In addition to breast implants, we manufacture a range of testicular, calf, gluteal, facial implants, and skin expanders of various shapes. In cases where specific dimensions are required, we use computer-aided designs which enable us to produce technically advanced custom-made implants with 3D technology. Our goal is to supply safe, high-quality devices to surgeons and their patients. Safety and quality are our top priorities. We support all innovations for the future in the field of plastic, reconstructive and aesthetic surgery and a large part of our budget is spent on research and development.

**sirius medical**

**STAND 16**

With its roots in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions to help physicians and hospitals manage growth and control costs. Sirius Pintuition®, powered by GPSDetect™ is CE marked and FDA 510(k) cleared. The system is an intuitive, wire-free surgical navigation system with a unique multi-sensor probe that provides real-time directional guidance using audio and visual feedback for unmatched precision to locate tumors easily and accurately. The system is simple, precise, and affordable. Sirius Medical has an experienced business development and surgical support team in the UK, Western Europe and the US. The team organizes training, shared learning and education to implement a broad use of the Pintuition surgical navigation system.



**STAND 12**

The Sloane Project is a national prospective cohort study of non-invasive breast neoplasia diagnosed through the NHS Breast Screening Programme. The Project commenced in 2003 to evaluate the radiological assessment, surgical management, pathology, adjuvant therapy and outcomes for non-invasive breast neoplasia. Accrual for patients with Ductal Carcinoma In Situ (DCIS) ceased in 2012 but is ongoing for patients with epithelial atypia/in situ neoplasia, along with the collection of follow-up and vital status data for all patients. The Sloane Project team are part of the Screening Quality and Assurance Service (SQAS) within the Medical Directorate at NHS England and NHS Improvement. Contact: [phe.sloaneproject@nhs.net](mailto:phe.sloaneproject@nhs.net)





# sirius medical

## Experience Sirius Pintuition<sup>®</sup>

powered by GPSDetect<sup>™</sup>

Hands-on symposium including lunch  
Time: 13.00 - 14.00  
Location: Room 12

Precise navigation in all cases

Scan here for more information 



## Personalised medicine helps guide breast cancer treatment decisions


The **ONLY** test that answers the following **three questions...**

Can chemotherapy be avoided?  
(Risk up to 15 years <sup>1,2</sup>)

What is the absolute benefit from chemotherapy?  
(Chemotherapy benefit <sup>3</sup>)

Can endocrine therapy be stopped after 5 years?  
(Risk between 5 and 15 years <sup>3</sup>)

...giving you **better treatment** and health outcomes



1. Filipits M. et al.: Clin Cancer Res. 2011; 17(18):6012-6020 / 2. Sesak I. et al.: Breast Cancer Res Treat. 2019 / 3. Filipits M. et al.: Clin Cancer Res. 2019

To find out more get in touch:

sourcebioscience.com | +44 (0) 115 973 9012 | enquiries@sourcebioscience.com



STAND 26

Source BioScience is an international provider of integrated state of the art Laboratory Services and Products. Supporting the NHS and private sector with Healthcare Diagnostic Services which comprises of Cellular Pathology and Clinical Diagnostics Services, offering a complete service for cut-up, processing, and reporting of wet surgical specimens and pre-prepared blocks or slides through our ISO 15189:2012 accredited laboratory. Source BioScience is a leading provider of laboratory services to improve Life Science, Drug Development and Patient Care. Now offering the EndoPredict precision medicine test designed for women with ER+, HER2- early-stage breast cancer (node-negative or node positive (1-3nodes), pre- or postmenopausal) which provides three separate results to optimize treatment for patients with breast cancer for better health and treatment outcomes.



STAND 8

Southern Scientific has many years of experience and expertise working in the specialist health sector. Indeed, as part of the LabLogic group, the company is a key supplier to the healthcare sector worldwide. We are the UK manufacturer of the C-Trak Apollo Probe System, which provides accurate and precise detection of radiation for use during sentinel node biopsies in breast, melanoma and other types of cancer. We are also the UK supplier of preloaded needles with I-125 seeds for tumour localisation.



STAND 41

Stryker's mission and approach towards technology remains to allow clinicians to "See More, and Do More" in surgery. In line with this we will be showcasing our leading Fluorescence Guided Surgery Platform; SPY PHI. The future of surgical visualisation is about standards or care, patient outcomes and reducing complications. Our SPY PHI fluorescence imaging platform has a wealth of clinical data showing increased standards of care and reduction of post-op complications. Our unique handheld, Spy Phi, imager and fluorescent imaging modalities allow the surgeons to visualise fluorescence without any disruption to surgical flow. We look forward to meeting you on our exhibition stand



STAND 4

Sysmex are the exclusive distributors of the Sentimag<sup>®</sup> system, the only non-radioactive option that offers both lesion localisation (Magseed<sup>®</sup>) and SLNB (Magtrace<sup>®</sup>) in the same platform. Magseed<sup>®</sup> has become the most widely adopted alternative to guide wires across Europe whilst Magtrace<sup>®</sup> now offers a 30 day injection window to eradicate delays associated with radioisotope. Sysmex also manufacture the NICE approved RD-210 (OSNA<sup>®</sup> system) which offers a fast, standardised and quantified (CK19 mRNA cps/ul) molecular lymph node analysis to ensure no metastasis is left undiscovered. Results of whole lymph node analysis, rather than sampling, are available in as little as 20 mins for those wanting to perform intraoperative assessment or can equally be analysed post-operatively to provide confidence in clinical decision making in an era of surgical and therapy de-escalation. Life Science (sysmex.co.uk)



STAND 6

The SILIMA<sup>®</sup> collection is one of the core segments of the THUASNE Group, whose expertise in orthopaedics and compression is known worldwide. In addition to a complete range of external breast forms in a wide variety of styles, our offering also includes various lingerie and swimwear series for daily comfort, safety and restoring the female silhouette. Drawing on many years of experience in the manufacture of high quality compression treatment aids, THUASNE offers a complete concept for the interdisciplinary therapy of lymphoedema and breast care. We look back on many years of international competence, especially in the field of thoracic care, and are now creating a uniquely coordinated all-round collection with breast forms, functional lingerie, swimwear and even compression clothing: Reliable, highly effective, easy to use and comfortable to wear.  
www.thuasne.co.uk  
www.silima.co.uk

# SPY-QP

## Fluorescence Assessment Software

Stryker is proud to present our fluorescence assessment software for use with the SPY-PHI system: **SPY-QP!** This software allows surgeons to further assess the intensity of the fluorescence signal through Relative Values (%) and a Color Maps mode.<sup>1</sup>



1. P46821 - User Guide, SPY-QP Fluorescence Assessment Software



### STAND 27

We are specialist in surgical retraction supplying double arm retractors for Axillar, Breast and Oncoplastic surgery. We manufacture our own retractor blades with detachable fibre light wand to ensure that the illumination (light fibres) gives maximum light to the operative site at all times during use. Simply replace the wand with a new strip once the light fibres start to dim through reprocessing. We also manufacture a V shaped blade (which is gentle) to use with the retractor to assist in Nipple Sparing procedures. Come try our range of Supercut scissors on the stand.



### STAND 22

Veracyte is a global diagnostics company that improves care throughout the patient journey. Our advanced diagnostic tests answer important clinical questions in several of the most prevalent cancers worldwide, helping patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our exclusive license to a best-in-class diagnostics instrument positions us to deliver our tests to patients globally through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit [www.veracyte.com](http://www.veracyte.com) and follow the company on Twitter (@veracyte).


### visit Belfast

### STAND 48

The ABS Conference will be held in Belfast in 2023 on the 15th and 16th May. The Visit Belfast stand will have ideas of what you can do in Belfast, travel information and other useful tips for delegates.



2nd generation test that more comprehensively informs treatment decisions.



**Adrian Wood**  
UK Country Manager  
at Veracyte

Email: [adrian@veracyte.com](mailto:adrian@veracyte.com)  
Mob: +44 7510 799 232

**Sam Jole**  
Associate Director Medical  
Affairs EMEA

Email: [sam@veracyte.com](mailto:sam@veracyte.com)  
Mob: +44 7824 950 364



CE-IVD  
MARKED  
GUIDELINES  
RECOMMENDED



**The ABS would like to thank all exhibiting companies for their support of the conference.**





The ABS would like to thank the following companies for sponsoring the ABS Conference 2022



Association of Breast Surgery Conference

Monday 15th –  
Tuesday 16th May 2023  
ICC, Belfast



For more details please visit the website

[www.associationofbreastsurgery.org.uk](http://www.associationofbreastsurgery.org.uk)





Association of Breast Surgery  
at The Royal College of Surgeons  
38-43 Lincoln's Inn Fields  
London WC2A 3PE

t: 020 7869 6855  
e: [office@absqbi.org.uk](mailto:office@absqbi.org.uk)  
w: [www.associationofbreastsurgery.org.uk](http://www.associationofbreastsurgery.org.uk)